Tumor Necrosis Factor-beta (TNF-β), also known as Lymphotoxin-alpha (LT-α), is a cytokine involved in systemic inflammation and one of the cytokines that make up the tumor necrosis factor family.
TNF-β is typically high expression in cancers with poor prognosis.
| Field |
Suggested Entry |
| Target |
LTA / lymphotoxin-α / TNF-β |
| Full Name |
Lymphotoxin alpha |
| Target Class |
TNF-superfamily cytokine |
| Main Receptors |
TNFR1/TNFRSF1A, TNFR2/TNFRSF1B, HVEM/TNFRSF14; LTBR/TNFRSF3 when complexed with LTB |
| Primary Biology |
Lymphocyte-derived inflammatory signaling, immune activation, antiviral response, apoptosis signaling, lymphoid tissue organization, secondary lymphoid organ development |
| Cancer Relevance |
Medium and context-dependent: may contribute to tumor-cell cytotoxicity, cancer immunity, lymphoid-structure formation, chronic inflammation, and tumor microenvironment remodeling depending on context |
| AD Relevance |
Low-medium: indirect relevance through TNF-family neuroinflammation; less established than TNF-α, TNFR1, or TNFR2 |
| Therapeutic Direction |
Context-dependent. Suppress excessive/pathological inflammatory signaling where appropriate, but avoid assuming that LTA inhibition is always beneficial because lymphotoxin signaling can also support immune defense and tumor surveillance. |
|